New Orleans, LA—March 10, 2018
When someone develops adult-acquired flatfoot deformity (AAFD), they are offered either a reconstruction or foot fusion depending on the severity of the flatfoot and their age. Typically reconstructions are performed in younger patients while older patients undergo fusions, even though it can limit mobility.
Researchers from Hospital for Special Surgery (HSS) presented study findings today at the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS) that were the first to compare the outcomes of reconstructions on older patients to those of a younger group.
The study evaluated patients over 65 with stage II AAFD to see if there are worse clinical outcomes or an increased number of subsequent surgical procedures following flatfoot reconstruction when compared to younger patients.
"Overall, flatfoot reconstruction provides better long-term outcomes and mobility of the foot when compared to foot fusions," said Scott J. Ellis, MD, foot and ankle surgeon at HSS and senior study author. "However, there is a chance that reconstruction could fail, and to avoid a long, arduous recovery with multiple surgeries, patients older than 65 commonly skip reconstruction and opt for a fusion."
"My colleagues and I wanted to investigate if this was still a viable option for elderly patients in the hopes of maintaining flexibility in their foot," Dr. Ellis added.
Over 130 HSS patients were assessed in three groups based on their age: less than 45 years old (young); 45 to 65 years old (middle-aged); and 65 years and older (old).
This study measured clinical outcomes using the Foot and Ankle Outcome Score (FAOS) and compared preoperative and postoperative scores at a minimum of two years. Findings indicated that patients in the older group did not demonstrate any differences in their outcomes compared with patients in the young and middle-aged groups.
Additionally, older patients were not more likely to undergo a subsequent removal of hardware or revision procedures than patients in the younger cohorts.
"Our initial hypothesis was that there would be increased complications for patients in the older group. However, we saw positive, consistent surgical outcomes across all age groups," said Dr. Ellis. "Depending on the severity of the condition, we believe a flatfoot reconstruction is a great option for patients regardless of their age. For the right patient, it can be the last surgery that they need."
Dr. Ellis believes that older patients have not often been offered a flatfoot reconstruction by their surgeons since there has not been enough research to critically review surgical outcomes. The loss of mobility with a fusion is something patients need to consider and discuss with their surgeon along with their expectations.
"This is strong evidence to support that flatfoot reconstruction can be an option for everyone, but we need to continue to follow patient clinical outcomes over an extended period of time to provide more data for this sparsely investigated topic," Dr. Ellis stated.
About HSS | Hospital for Special Surgery
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the eighth consecutive year) and No. 3 in rheumatology by U.S. News & World Report (2017-2018). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients and performed more than 32,000 surgical procedures. People from all 50 U.S. states and 80 countries travelled to receive care at HSS. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The culture of innovation is accelerating at HSS as 130 new idea submissions were made to the Global Innovation Institute in 2017 (almost 3x the submissions in 2015). The HSS Education Institute is the world’s leading provider of education on the topic on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.